Paglalarawan

Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. Ayon sa StrategyHelix, the intravenous immunoglobulin market in United States is expected to increase by US$ 2.5 bilyon sa panahon ng 2022-2028, expanding at a CAGR of 6.4% sa panahon ng pagtataya.

Ang ulat ay nagbibigay ng napapanahong data ng laki ng merkado para sa panahon 2018-2021 at forecast na 2028 covering key market aspects like sales value for intravenous immunoglobulin. The United States intravenous immunoglobulin market is segmented on the basis of application, and end user. Based on application, the intravenous immunoglobulin market in United States is categorized into chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, iba pa ang iba. The immunodeficiency diseases segment held the largest share of the United States intravenous immunoglobulin market in 2021 at inaasahang gaganapin ang share nito sa panahon ng pagtataya. Sa batayan ng end user, the intravenous immunoglobulin market in United States has been segmented into homecare, mga ospital & clinics.

The United States intravenous immunoglobulin market is highly competitive. Key companies profiled in the report include ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited. Competitive landscape gives a description of the competitive nature of the intravenous immunoglobulin market in United States and a description of the leading companies. Key financial deal na kung saan ay hugis ang merkado sa mga nakaraang taon ay nakilala.

Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the intravenous immunoglobulin market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

Saklaw ng Ulat

Paglalapat: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, iba pa ang iba
End user: homecare, mga ospital & clinics
Taon na itinuturing: Ang ulat na ito ay sumasaklaw sa panahon 2018 sa 2028
Nabanggit na kumpanya: ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited

Mga Pangunahing Benepisyo para sa mga Stakeholder

– Get a comprehensive picture of the United States intravenous immunoglobulin market
– Kilalanin ang mga estratehiya sa rehiyon at mga estratehikong prayoridad batay sa lokal na data
– Pinpoint ang mga sektor ng paglago at mga trend para sa pamumuhunan

Talaan ng mga Nilalaman

Bahagi 1. Panimula
– Saklaw ng pag aaral
– Panahon ng pag aaral
– Saklaw ng heograpiya
– Paraan ng pananaliksik
Bahagi 2. Intravenous immunoglobulin market overview
Bahagi 3. Market breakdown by application
– Chronic inflammatory demyelinating polyneuropathy (CIDP)
– Chronic lymphocytic leukemia
– Congenital HIV/AIDS
– Guillain-barre syndrome (GBS)
– Hypogammaglobulinemia
– Immune thrombocytopenic purpura (ITP)
– Immunodeficiency diseases
– Kawasaki disease
– Multifocal motor neuropathy (MMN)
– Myasthenia gravis
– Ang iba naman
Bahagi 4. Pagkasira ng merkado sa pamamagitan ng end user
– Homecare
– Hospitals & clinics
Bahagi 5. Mga pangunahing kumpanya
– ADMA Biologics Inc.
– Biotest AG
– CSL Limited
– Grifols, S.A.
– Johnson & Johnson
– Kedrion Biopharma Inc. (Kedrion SpA)
– LFB S.A.
– Octapharma AG
– Takeda Pharmaceutical Company Limited
Tungkol sa StrategyHelix
Pagtanggi